Known Ligand-Derived Ligand Discovery Services

* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.

Many degradation programs already hold something far more valuable than an empty binding pocket: a ligand with a confirmed binding mode, a structure–activity relationship, and sometimes years of accumulated target knowledge. The ligand-first strategy builds on this asset directly. Instead of screening reactive fragments from scratch, a known target binder is used as the recognition scaffold, and an electrophilic warhead is installed at a position that places it within reach of a nearby nucleophilic residue. The result is a covalent ligand whose selectivity is inherited from recognition rather than from raw reactivity—an increasingly attractive starting point for covalent degrader design.

BOC Sciences provides known ligand-derived warhead discovery services for targeted protein degradation, covering parent ligand evaluation, covalent feasibility analysis, exit vector selection, structure-guided warhead installation, analogue synthesis, and covalent engagement validation. By combining computational placement, medicinal chemistry, and kinetic characterization, we convert validated ligands into warhead-bearing starting points that are ready for linker assembly and degrader construction.

Request a Consultation Explore Services
Services

BOC Sciences' Known Ligand-Derived Warhead Discovery Services

BOC Sciences delivers known ligand-derived warhead discovery as a connected workflow, from judging whether your parent ligand can support covalent engagement to delivering an optimized, degrader-compatible lead. Each stage is designed to protect the two assets you already have—binding affinity and structural knowledge—while adding the covalent dimension your degrader program needs. Our broader capabilities in ligand design for target protein provide the foundation for every project.

Gene Therapy

Known Ligand Evaluation and Covalent Feasibility Analysis

We first determine whether your ligand is a sound foundation for covalent design, through:

  • Ligand evidence review service: assessment of the parent ligand's binding mode, available co-crystal or modeled structures, and reported SAR to judge how much design confidence it can carry into a covalent program.
  • Residue-pairing analysis service: identification of cysteine, lysine, serine, or threonine residues within bonding distance of the ligand, including evaluation of solvent exposure and local pKa.
  • Feasibility recommendation service: a written go/no-go assessment that nominates the most promising residue–warhead pairing, flags competing residues, and defines design risks before synthesis begins.
Gene Therapy

Exit Vector Identification and Attachment Site Selection

Where the warhead is attached decides everything downstream. BOC Sciences selects attachment positions through:

  • Solvent-exposure mapping service: location of positions on the parent ligand that point toward the target residue while remaining tolerant of structural addition, supported by protein-ligand structure analysis.
  • Substitution tolerance service: cross-reading of SAR data and covalent virtual screening to rank candidate attachment sites by how likely they are to preserve the parent binding pose.
  • Synthetic accessibility service: early route check on each candidate position, so the sites we recommend are practical to elaborate rather than only elegant on paper.
Gene Therapy

Warhead Analogue Synthesis and Covalent Engagement Validation

Once a design direction is fixed, we build and verify the covalent ligand through:

  • Warhead installation service: late-stage installation of chemotype-matched electrophiles—acrylamides, α-cyanoacrylamides, nitriles, aldehydes, boronic acids, and related motifs—onto the validated scaffold positions.
  • Covalent engagement validation service: intact-protein mass spectrometry, dilution and washout experiments, and adduct characterization to confirm that labeling occurs at the intended residue and behaves as designed.
  • Parent-versus-analogue comparison service: side-by-side binding affinity measurement of the parent ligand and its warhead-modified analogues, quantifying exactly what the covalent modification cost or added.
Gene Therapy

Optimization for Degrader Compatibility and Lead Delivery

BOC Sciences prepares the validated covalent ligand for its role inside a degrader through:

  • Warhead SAR optimization service: tuning of electrophile electronics, sterics, and substitution to balance association rate, adduct lifetime, and selectivity against the requirements of your degradation strategy.
  • Linker compatibility service: evaluation of how conjugation at the chosen exit vector affects binding and covalent geometry, supported by our linker design and optimization services.
  • Lead delivery service: a prioritized lead set with defined exit vectors, kinetic profiles, and a handoff plan into PROTAC design services for E3 ligand pairing and ternary complex work.
Ligand Sources

Known Ligand Sources for Warhead Derivatization

A covalent degrader is only as good as the scaffold it is built on, so the choice of starting ligand deserves the same rigor as the warhead design itself. BOC Sciences works across the full range of ligand sources, and our warhead library supplies chemically diverse electrophile structures and building blocks to pair with any of them.

Literature-Reported and Database-Derived Ligands

Public literature, patent-free chemical matter, and ligand databases contain thousands of target binders whose structures and SAR have already been described. BOC Sciences mines these resources to shortlist scaffolds that combine a credible binding mode with a residue positioned for covalent engagement, then proposes derivatization options ranked by design confidence and synthetic feasibility.

Established Small-Molecule Inhibitors and Reference Compounds

Well-characterized inhibitor chemotypes—especially across kinase and other enzyme families—offer the strongest starting points, because their binding poses, resistance mutation maps, and selectivity boundaries are extensively documented. We evaluate whether a covalent group can be grafted onto such scaffolds without disturbing the pharmacophore, and design analogue sets that compare warhead placement options around the same core.

Fragment-Based Screening Hits

Fragment hits bind efficiently but weakly, which makes them ideal candidates for warhead-driven affinity maturation: adding the right electrophile can convert a millimolar fragment into a ligand whose covalent engagement compensates for modest non-covalent affinity. BOC Sciences maps fragment binding orientations, identifies solvent-exposed growth points near candidate residues, and elaborates hits into covalent ligands with measured kinetic behavior.

Customer-Supplied and In-House Ligands

Many clients arrive with proprietary binders, internal SAR, or unpublished structures they prefer to keep in confidence. We accept customer-supplied ligands and structural data as the direct starting material for derivatization, and can also contribute ligand candidates from our in-house collections when a program needs additional scaffold diversity around a challenging residue.

Troubleshooting

Design Challenges We Solve in Known Ligand-Derived Warhead Programs

Converting a known ligand into a covalent one is a delicate operation: the warhead must reach its residue without breaking the recognition that makes the scaffold worth using. BOC Sciences addresses the recurring failure modes through structural analysis, kinetic measurement, and iterative medicinal chemistry.

Preserving Parent Ligand Binding After Warhead Introduction

Adding an electrophilic group can distort the parent pharmacophore, clash with the pocket, or shift the binding pose away from the orientation the residue pairing assumed. BOC Sciences ranks attachment sites using SAR cross-reading, structural comparison, and modeling, then verifies each synthesized analogue against the parent ligand in matched assays, so any loss of recognition is detected and corrected early rather than discovered after degrader assembly.

Achieving Productive Warhead-Residue Geometry

A reactive group placed at the wrong vector reacts slowly, misses the residue, or labels a neighboring nucleophile instead. BOC Sciences models the covalent approach trajectory for each candidate attachment site, evaluates residue accessibility across conformational states, and screens short analogue sets at alternative exit vectors, using adduct-site confirmation to verify that the geometry works in solution and not only in silico.

Balancing Covalent Reactivity, Kinetics, and Selectivity

Warheads that are too reactive label off-target nucleophiles; warheads that are too gentle never achieve occupancy. BOC Sciences treats reactivity as a tunable variable rather than a fixed property, comparing chemotypes and substituent patterns for association rate, adduct lifetime, and competition with free thiols, so the installed warhead delivers the residence-time window your degrader actually needs—whether reversible or irreversible engagement is intended.

Maintaining Target Engagement After Linker Attachment

A warhead-modified ligand that works beautifully alone can lose engagement once a linker and E3 ligand are attached, because conjugation changes the exit vector geometry or sterically blocks the residue. BOC Sciences evaluates binding and covalent labeling after linker installation, iterates conjugation position and linker class, and coordinates the fix with our linker binding site selection and design expertise before the program commits to full degrader synthesis.

Facing Challenges in Known Ligand-Derived Warhead Design?

Whether your project involves preserving parent ligand affinity, identifying a suitable reactive residue, optimizing covalent reactivity, or maintaining target engagement after linker attachment, BOC Sciences can help evaluate the problem and develop a practical modification strategy.

Discuss Your Design Challenges

Workflow

Our Workflow for Known Ligand-Derived Warhead Discovery

01

Starting Ligand Review and Feasibility Assessment

We review the parent ligand, its binding mode, SAR coverage, and candidate nucleophilic residues, then issue a residue–warhead pairing recommendation together with the covalent kinetic profile the final degrader should aim for.

02

Reactive Residue Mapping and Warhead Design

Covalent docking and pose analysis define the approach geometry between ligand and residue, candidate exit vectors are ranked for binding-pose tolerance, and a focused analogue design is produced with chemotype options matched to the residue type.

03

Warhead-Modified Ligand Synthesis and Covalent Validation

Analogues are synthesized with late-stage warhead installation, then validated by intact-protein mass spectrometry, washout experiments, and affinity comparison against the parent ligand to confirm residue-specific, appropriately reversible or persistent engagement.

04

Structure-Guided Optimization and PROTAC Compatibility Assessment

Lead analogues are optimized on exit vector, kinetics, and selectivity, and delivered with a conjugation-site and linker-compatibility assessment that feeds directly into covalent covalent PROTAC technology development for E3 pairing and degradation evaluation.

Why Us

Why Choose BOC Sciences for Known Ligand-Derived Warhead Discovery?

Integrated Computational Design and Experimental Validation

Covalent docking, exit-vector ranking, and kinetic prediction run inside the same team that synthesizes and tests the analogues, so a design recommendation and its experimental verification are never separated by a handoff.

Physical Ligand and Warhead Library Resources

Our curated libraries of electrophile chemotypes, building blocks, and scaffold analogues allow candidate warheads to be paired with parent ligands quickly, and provide immediate chemical diversity when the first derivatization round needs expansion.

Experimental Covalent Evaluation Platform

Intact-protein mass spectrometry, washout and exchange experiments, affinity comparison, and degradation ability assay access from the same compound batch close the loop between warhead design and degradation outcome.

Custom Synthesis Capabilities for Ligand-Derived Warheads

Late-stage warhead installation, sensitive electrophile handling, and focused analogue series are delivered through our custom PROTAC synthesis services chemistry platform, keeping design iterations fast and chemically reliable.

Frequently Asked Questions (FAQ)

Frequently Asked Questions

Still have questions?

Contact Us

Known ligand-derived warhead discovery is a ligand-first covalent design approach. It starts with a small molecule that already recognizes the target protein, then evaluates whether an electrophilic warhead can be introduced at a suitable position to engage a nearby nucleophilic residue. The design must preserve important noncovalent interactions while placing the reactive group in a productive orientation. This differs from electrophile-first discovery, which begins by screening reactive compounds or covalent fragments and then optimizing their protein recognition. BOC Sciences evaluates parent ligands, binding modes, reactive residues, and modification options before preparing and testing selected analogues.

Yes. If you have identified a target protein but do not yet have a suitable ligand, the project can begin with ligand sourcing and discovery rather than immediate warhead derivatization. Potential starting points include literature-reported structures, database-derived compounds, established inhibitors, reference ligands, and fragment screening hits. BOC Sciences can review available target information, identify candidate binders, and use computational screening and experimental binding assessment to prioritize starting molecules. Once a ligand demonstrates a credible binding mode and suitable chemical positions, its proximity to accessible reactive residues can be evaluated. A validated ligand provides the foundation for rational ligand-derived warhead design.

Attachment-site selection begins by identifying which parts of the parent ligand are essential for target recognition and which positions can tolerate modification. The team then examines solvent exposure, local steric environment, ligand conformation, and the distance and orientation between the proposed electrophile and a potentially reactive residue. A nearby cysteine alone does not establish covalent feasibility; its accessibility and local chemical environment also matter. Covalent docking and structural analysis can compare alternative attachment vectors, but predictions should be tested experimentally. The preferred site preserves key ligand-protein contacts while positioning the warhead for productive covalent engagement.

Validation combines evidence that the modified ligand still recognizes the target with direct evidence of covalent adduct formation. Depending on the protein and warhead, intact-protein mass spectrometry can detect mass shifts consistent with adduct formation, while peptide-level mass spectrometry can help localize the modified residue. Binding or target-engagement assays compare the parent ligand with the modified analogue, and time-dependent measurements characterize reaction behavior. For reversible warheads, dilution or washout experiments can help assess adduct dissociation. Selectivity is evaluated by testing relevant related proteins or competing nucleophiles rather than relying on a single binding result.

A ligand-derived covalent binder can be a starting point for PROTAC development, but covalent engagement alone does not establish degrader suitability. The modified ligand must retain target recognition after linker attachment, provide a usable linker exit vector, and remain compatible with formation of a productive target-E3 ligase complex. BOC Sciences can evaluate linker attachment positions, ligand orientation, and structural compatibility, then support linker assembly and degrader evaluation. Relevant experiments should assess target engagement alongside protein degradation, because stronger or longer-lasting binding does not automatically translate into improved degradation. The choice between reversible and irreversible covalent chemistry should be guided by the intended degradation mechanism.

* PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.

BOC Sciences Support

Please contact us with any specific requirements and we will get back to you as soon as possible.

  • Verification code
Inquiry Basket